Alzheimer’s

Biotech By Adam Feuerstein, Damian Garde, and Meg Tirrell

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

Biotech By Matthew Herper, Adam Feuerstein, and Damian Garde

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Pharmalot By Ed Silverman

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

Biotech By Damian Garde and Adam Feuerstein

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Biotech By Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Biotech By Damian Garde

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Biotech By Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

In the Lab By Sharon Begley

New prize offers $2 million for finding key to Alzheimer’s in past research

Pharma By Sharon Begley

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalot By Ed Silverman

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

Adam's Take By Adam Feuerstein

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

Alzheimer's brain illustration - Loss of connection between cells

Pharmalot By Ed Silverman

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

Biotech By Sharon Begley

In small Alzheimer’s study, hints of modest benefit from unusual drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

Pharmalot By Ed Silverman

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

Signal Podcast By Luke Timmerman and Meg Tirrell

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions

Health By Sharon Begley

Dramatic decline in dementia seen among older adults in the US

Health By Judith Graham

Loneliness is bad for your health. This new campaign aims to curb isolation

In the Lab By Sharon Begley

Their brains had the telltale signs of Alzheimer’s. So why did they still have nimble minds?

Politics By Rebecca Robbins

Alzheimer’s is eroding his memory, but not his determination to vote

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill

Gut Check By Sharon Begley

Can curcumin spice treat Alzheimer’s disease?

In the Lab By Bryan Marquard — Boston Globe

MIT’s Susan Lindquist, a pioneer in science, dies at 67

Pharmalot By Ed Silverman

Most Read

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Watch: Genetic tests promised to help me achieve peak fitness. What I got was a fiasco

Hospitalized adults need their caregivers — they aren’t visitors

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s

Why Nestlé — yes, that Nestlé — is acting a lot like a drug company

All Coverage

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Startup Arkuda targets rapidly advancing, rare form of dementia

New prize offers $2 million for finding key to Alzheimer’s in past research

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

In small Alzheimer’s study, hints of modest benefit from unusual drug

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions

Dramatic decline in dementia seen among older adults in the US

Loneliness is bad for your health. This new campaign aims to curb isolation

Their brains had the telltale signs of Alzheimer’s. So why did they still have nimble minds?

Alzheimer’s is eroding his memory, but not his determination to vote

Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill

Can curcumin spice treat Alzheimer’s disease?

MIT’s Susan Lindquist, a pioneer in science, dies at 67

Pharmalot, Pharmalittle: New bill would create review board for drug prices